Intestinal Cell News Volume 4.23 | Jun 22 2018

TOP STORY

CEMIP, a New Player in the Acquired Resistance to Targeted Therapies

Researchers showed that the CEMIP protein plays a role in resistance to targeted therapies for colorectal cancers. By associating one targeted therapy with a pharmacological treatment that inhibits this protein, scientists could treat relapses in patients with this type of tumor. [Press release from the University of Liege discussing online prepublication in Cancer Research] Press Release | Abstract

(Ranked by impact factor of the journal)

LncRNA SNHG7 Sponges miR-216b to Promote Proliferation and Liver Metastasis of Colorectal Cancer through Upregulating GALNT1

High level of SNHG7 was observed in colorectal cancer (CRC) cell lines compared to normal colon cells. SNHG7 overexpression promoted the proliferation, migration, and invasion of CRC cell lines, while SNHG7 depletion inhibited invasion and cell viability in vitro. [Cell Death Dis] Full Article

NOD2 Modulates Serotonin Transporter and Interacts with TLR2 and TLR4 in Intestinal Epithelial Cells

Nucleotide oligomerization domain (NOD)2 activation inhibited serotonin transporter (SERT) activity in Caco-2/TC7 cells, mainly due to the decrement of SERT molecular expression, with RIP2/RICK being the intracellular pathway involved in this effect. [Cell Physiol Biochem] Full Article

Heterocyclic Analogs of Sulforaphane Trigger DNA Damage and Impede DNA Repair in Colon Cancer Cells: Interplay of HATs and HDACs

Structural analogs of the anticancer agent sulforaphane were investigated as modifiers of histone deacetylase and histone acetyltransferase activity, and for effects on DNA damage/repair pertinent to human colorectal cancer. [Mol Nutr Food Res] Abstract

WDR5 Supports Colon Cancer Cells by Promoting Methylation of H3K4 and Suppressing DNA Damage

WDR5 was overexpressed in colon tumors and colon cancer cell lines at the mRNA and protein level. WDR5 depletion reduced cell viability in HCT116, LoVo, RKO, HCT15, SW480, SW620, and T84 colon cancer cells. [BMC Cancer] Full Article

ALDH1A Inhibition Sensitizes Colon Cancer Cells to Chemotherapy

Scientists focused on the aldehyde dehydrogenase type 1 (ALDH1) expression in colon cancer-derived cell lines HT-29/eGFP, HCT-116/eGFP and LS-180/eGFP, and its role in the chemoresistance and tumorigenic potential. [BMC Cancer] Full Article

Annonaceous Acetogenin Mimic AA005 Suppresses Human Colon Cancer Cell Growth In Vivo through Downregulation of Mcl-1

The authors investigated the effects of AA005 on human colon cancer cell lines in vivo. Human colon carcinoma cell line SW620 xenograft nude mice were treated with AA005 for 21 days. AA005 administration markedly inhibited the tumor growth via promoting nuclear translocation of apoptosis-inducing factor (AIF) and inducing AIF-dependent cell death. [Acta Pharmacol Sin] Abstract

LncRNA FTX Sponges miR-215 and Inhibits Phosphorylation of Vimentin for Promoting Colorectal Cancer Progression

Functional analyses demonstrated that knockdown of long noncoding RNA (lncRNA) five prime to Xist (FTX) markedly inhibited colorectal cancer cell proliferation, migration, and invasion in vitro. [Gene Ther] Abstract

Colon Organoid Formation and Cryptogenesis Are Stimulated by Growth Factors Secreted from Myofibroblasts

Researchers investigated whether conditioned medium (CM) from colon mesenchymal cells can stimulate colonosphere and organoid cryptogenesis. They prepared conditioned medium from WEHI-YH2 cells; the CM stimulated both colonosphere formation and organoid cryptogenesis in vitro. [PLoS One] Full Article

Hsa-miR-370 Inhibited P-Selectin-Induced Cell Adhesion in Human Colon Adenocarcinoma Cells

Hsa-miR-370 inhibited the expression of sLex in colo-320 cells, which repressed the binding of P-selectin, and led to reduced cell attachment and spread. [Mol Cell Biochem] Abstract

miR-29a Inhibited Intestinal Epithelial Cells Autophagy Partly by Decreasing ATG9A in Ulcerative Colitis

Investigators showed that the overexpression of miR-29a not only suppressed the production of GFP-LC3 autophagy spots but also inhibited the level of LC3II/LC3I and upregulated the expression of P62 in HT29 and HCT116 cells. [Anticancer Drugs] Abstract

Inflammatory Bowel Disease: New Therapies from Antisense Oligonucleotides

The authors summarize the available pre-clinical and clinical data for antisense oligonucleotides and oligonucleotides to provide a comprehensive understanding of the rationale and mechanism of action of these compounds in inflammatory bowel disease. [Ann Med] Abstract

Visit our reviews page to see a complete list of reviews in the intestinal cell research field.

Array BioPharma to Present Overall Survival Results from the Phase III BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer

Array BioPharma Inc. announced that it will present updated safety and efficacy results, including overall survival data, from the safety lead-in of the Phase III BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF-mutant colorectal cancer (CRC). [Press release from Array BioPharma Inc. discussing research to be presented at at the ESMO 20^th World Congress on Gastrointestinal Cancer, Barcelona] Press Release

Dr. Meritxell Huch reviews organoid culture and applications for intestinal, hepatic, and pancreatic tissues. Watch Now

Study into the Causes of Crohn’s Disease Hits Major Milestone

After ten years and a worldwide effort, Crohn’s and Colitis Canada announced that the world-renowned Genetic, Environmental, Microbial (GEM) Project has reached its goal of 5,000 participants. Launched in 2008 at Mount Sinai Hospital in Toronto, the GEM Project is the world’s largest clinical study investigating the causes of Crohn’s disease. [Crohn’s and Colitis Canada] Press Release

Exploring a New Treatment for Metastatic Colorectal Cancer

Rutgers Cancer Institute of New Jersey is offering a clinical trial targeting an advanced form of colorectal cancer with a combination vaccine/immunotherapy drug treatment. [Rutgers Cancer Institute of New Jersey] Press Release

Trump’s Plan to Reshuffle Government Strikes Familiar Notes

President Donald Trump proposed reorganizing parts of the federal government in ways that should sound very familiar to those who follow U.S. science policy. The plan, labeled “Delivering Government Solutions in the 21^st Century,” would affect federal research agencies in ways great and small. [ScienceInsider] Editorial

Hundreds of U.S. Scientists Urge More Transparency in Animal Research

Breaking with a history of reticence, nearly 600 scientists, students, and lab animal workers published a letter in USA Today that calls on U.S. research institutions to “embrace openness” about their animal research. [ScienceInsider] Editorial

NEW Host and the Environment in IBD: Scientific Advances Leading to New Therapeutics (A2)
January 13-17, 2019
Taos, New Mexico, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Colorectal Cancer (Dalhousie University)

PhD position – Inflammatory Bowel Disease (Universitätsmedizin Berlin)

Postdoctoral Fellow Position – Intestinal Research (Vanderbilt University Medical Center)

Postdoctoral Position – Cancer Biology and Metastasis (MD Anderson Cancer Center)

Associate/Full Researcher – Cancer Biology (University of Hawaii Cancer Center)

Postdoctoral Position – Human Mucosal Immunology/Inflammatory Bowel Disease (Weill Cornell Medicine)

Postdoctoral Positions – Colon Stem Cells and Carcinogenesis (Johns Hopkins University School of Medicine)

Postdoctoral Fellowship – Inflammatory Bowel Disease (European Molecular Biology Laboratory)

Academic Position – Cancer Research (Cedars-Sinai Medical Center)

Postdoctoral Position – Digestive Health (University of California, Irvine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Intestinal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.